<DOC>
	<DOCNO>NCT01730430</DOCNO>
	<brief_summary>To establish cutoff value use ratio CSF tau Aβ42 ( tau/Aβ42 ) distinguish patient wth mild moderate Alzheimer 's disease ( AD ) health elderly control subject . The investigator hypothesize cutoff find least 80 % sensitivity 60 % specificity .</brief_summary>
	<brief_title>Cerebrospinal Fluid ( CSF ) Biomarkers Alzheimer 's Disease ( AD ) Non-AD Dementias</brief_title>
	<detailed_description>This study enroll 50 AD subject , 50 normal control approximately 20 subject non-AD dementia . There 2 visit ( 30 day apart ) , telephone follow-up visit . This protocol include treatment subject . Lumbar puncture phlebotomy routine clinical task associate low level risk . All adverse event document review PI .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Each subject must ≥ 55 ≤ 85 year age . Each subject must able read 6th grade level , determine investigator , must history academic achievement and/or employment sufficient exclude mental retardation . Each subject must result clinical laboratory test , physical examination , vital sign within normal limit clinically acceptable investigator within 28 day prior enrollment . Each subject ( legal representative ) must sign informed consent form scope nature investigation explain , screen assessment . Additional Inclusion Criteria Normal Controls : Must global Clinical Dementia Rating ( CDR ) score 0 . Must MiniMental State Examination ( MMSE ) score ≥ 28 . Must Zscore ≥ 1.0 cognitive domain memory ( include delay recall ) , language , executive function attention , visuoconstruction neuropsychological test choice adjustment age , gender , education level indicate . Additional Inclusion Criteria AD Subjects : Must meet criteria diagnosis probable AD base 1. National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion , 2. Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSM IV TR ) criterion AD . Must MMSE score ≥ 15 ≤ 26 . Must clear history cognitive functional decline least one year either 1. document medical record 2. documented history informant know subject well . Must MRI CT scan consistent diagnosis AD within 12 month prior enrollment . Exclusion Criteria AD Subjects Normal Controls The subject Rosen modify Hachinski Ischemia Score &gt; 4 . The subject known history stroke . The subject evidence clinically relevant unstable neurological psychiatric disorder ( AD subject AD ) . The subject history alcoholism drug dependency/abuse within last 5 year enrollment . The subject ongoing uncontrolled , clinically significant medical condition , judgment investigator , subject 's participation trial would pose significant medical risk subject . The subject participate within last two month clinical trial novel therapeutic agent ( e.g . bapineuzumab ) ever clinical trial AD vaccine . Pregnancy Additional Inclusion Exclusion Criteria Subject nonAD dementia Standard clinical diagnostic criterion accept field nonAD dementia use Institution .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>non-AD dementia</keyword>
	<keyword>healthy elderly control</keyword>
</DOC>